Khoukaz Taline
University of Southern California/Norris Cancer Center and Hospital, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):20-7. doi: 10.1016/j.soncn.2006.01.012.
To highlight key issues in the administration of cancer therapies that target the EGFR.
Published clinical trials of anti-EGFR therapy, secondary literature on the administration of anticancer drugs, and illustrative case study reports.
Anti-EGFR agents represent a new class of therapy. It is important for nurses to acquire familiarity with the specific issues related to the administration of anti-EGFR agents. Preparedness and active patient monitoring can minimize the impact of toxicities (including interstitial lung disease, infusion reactions, and metabolic alterations) and help ensure the delivery of full treatment courses.
Nurses familiar with the administration issues and the severe adverse events associated with anti-EGFR therapy will be better equipped to manage them effectively.
强调针对表皮生长因子受体（EGFR）的癌症治疗管理中的关键问题。
已发表的抗EGFR治疗临床试验、关于抗癌药物管理的二手文献以及说明性案例研究报告。
抗EGFR药物代表了一类新的治疗方法。护士熟悉与抗EGFR药物管理相关的具体问题非常重要。做好准备并积极监测患者可以将毒性（包括间质性肺病、输液反应和代谢改变）的影响降至最低，并有助于确保完整疗程的实施。
熟悉抗EGFR治疗相关管理问题和严重不良事件的护士将更有能力有效地应对这些问题。
